TERF1 interacting nuclear factor 2
Ultimo aggiornamento 18 Ago 2020
Rispetta le linee guida editoriali
- ScaricaScarica
- Condividi
- Language
- Discussione
- Versione audio
- Aggiungi alle fonti preferite su Google
L TINF2 gene provides instructions for making part of the shelterin protein complex. This complex consists of a group of proteins that work together to help maintain structures known as telomeres, which are found at the ends of chromosomes. Telomeres help protect chromosomes from abnormally sticking together or breaking down (degrading).
Normal function
L TINF2 gene provides instructions for making part of the shelterin protein complex. This complex consists of a group of proteins that work together to help maintain structures known as telomeres, which are found at the ends of chromosomes. Telomeres help protect chromosomes from abnormally sticking together or breaking down (degrading).
The shelterin complex helps protect telomeres from the cell's DNA repair process. Without the protection of shelterin, the repair mechanism would sense the chromosome ends as abnormal breaks in the DNA sequence and either attempt to join the ends together or initiate cellular self-destruction (apoptosis).
Conditions referring to this gene or chromosome
Altri nomi
(TRF1)-interacting nuclear factor 2 variant 1
TERF1 (TRF1)-interacting nuclear factor 2
TERF1-interacting nuclear factor 2
TERF1-interacting nuclear factor 2 isoform 1
TERF1-interacting nuclear factor 2 isoform 2
TIN2
TINF2_HUMAN
TRF1-interacting nuclear protein 2
Related patient information and medicines
Patient information leaflet
Controlla le tue medicine per interazioni
Use this verificatore di interazioni tra farmaci e medicinali per see whether your medicines, supplements, vitamins, foods, or certain health conditions may interact with each other. It can help you understand potential risks, avoid unwanted side effects, and decide when it’s important to speak to a pharmacist, GP, or other healthcare professional. The tool is.
Patient information leaflet
Posso prendere Atorvastatina ed Eplerenone insieme?
It is generally safe to take these two medications together. Why this happens Atorvastatin is a cholesterol-lowering medicine (statin) and eplerenone is a potassium-sparing diuretic (water pill). They are processed by the body using different pathways and do not interfere with how the other works. Disclaimer This information is for general.
Patient information leaflet
Tratto falciforme
If you inherit a gene from one of your parents, called a sickle cell gene, you have a condition called sickle cell trait. If you inherit a sickle cell gene from both parents, you get a double dose of the sickle cell gene. This causes a condition called sickle cell disease (SCD). What is sickle cell trait. Sickle cell trait means having one gene.
Patient information leaflet
Antibiotici
Antibiotics are medicines that treat bacterial infections, ma they don’t affect viruses (like colds or flu). Using the right antibiotic correctly and completing the full course helps ensure recovery and prevent resistance. What are antibiotics. Antibiotics are a group of medicines that are used to treat bacterial infections. Antibiotics are.
Patient information leaflet
Cause del cancro
Certain risk factors are known per increase the chance that one or more of your cells will become abnormal and lead to cancer. How does cancer start. The body is made up from millions of tiny cells. Different parts of the body such as organs, bones, muscles, skin and blood are made up from different specialised cells. Most cells have a centre.
%20together%3F/og.png)
Patient information leaflet
Posso prendere Atorvastatina e Rybelsus (semaglutide) insieme?
However, beca... Why this happens Atorvastatin is a statin used to lower cholesterol, primarily processed by the liver (CYP3A4 enzyme). Rybelsus is a GLP-1 receptor agonist used for blood sugar control. While Rybelsus slows down how quickly the stomach empties, it has not been shown to significantly change how the body absorbs or processes.
Ulteriori letture e riferimenti
- TERF1 interacting nuclear factor 2; MedlinePlus, National Library of Medicine.
- Ballew BJ, Savage SA. Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2013 Jun;6(3):327-37. doi: 10.1586/ehm.13.23.
- Baran I, Nalcaci R, Kocak M. Dyskeratosis congenita: clinical report and review of the literature. Int J Dent Hyg. 2010 Feb;8(1):68-74. doi: 10.1111/j.1601-5037.2009.00364.x.
- Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood. 2008 May 1;111(9):4446-55. doi: 10.1182/blood-2007-08-019729. Epub 2008 Jan 31.
- Calado RT. Telomeres and marrow failure. Hematology Am Soc Hematol Educ Program. 2009:338-43. doi: 10.1182/asheducation-2009.1.338.
- Chan SS, Chang S. Defending the end zone: studying the players involved in protecting chromosome ends. FEBS Lett. 2010 Sep 10;584(17):3773-8. doi: 10.1016/j.febslet.2010.06.016. Epub 2010 Jun 19.
- Kirwan M, Dokal I. Dyskeratosis congenita, stem cells and telomeres. Biochim Biophys Acta. 2009 Apr;1792(4):371-9. doi: 10.1016/j.bbadis.2009.01.010. Epub 2009 Feb 7.
- Nishio N, Kojima S. Recent progress in dyskeratosis congenita. Int J Hematol. 2010 Oct;92(3):419-24. doi: 10.1007/s12185-010-0695-5. Epub 2010 Oct 1.
- Sasa GS, Ribes-Zamora A, Nelson ND, Bertuch AA. Three novel truncating TINF2 mutations causing severe dyskeratosis congenita in early childhood. Clin Genet. 2012 May;81(5):470-8. doi: 10.1111/j.1399-0004.2011.01658.x. Epub 2011 Apr 7.
- Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet. 2008 Feb;82(2):501-9. doi: 10.1016/j.ajhg.2007.10.004. Epub 2008 Jan 31.
- Walne AJ, Dokal I. Advances in the understanding of dyskeratosis congenita. Br J Haematol. 2009 Apr;145(2):164-72. doi: 10.1111/j.1365-2141.2009.07598.x. Epub 2009 Feb 4.
- Walne AJ, Vulliamy T, Beswick R, Kirwan M, Dokal I. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood. 2008 Nov 1;112(9):3594-600. doi: 10.1182/blood-2008-05-153445. Epub 2008 Jul 30.
Partecipa alla conversazione
Condividi i tuoi pensieri o esperienze con gli altri nel nostro comunità di pazienti.
Chiedi, condividi, connettiti.
Esplora le discussioni, fai domande e condividi esperienze su centinaia di argomenti di salute.
Iscriviti alla newsletter di Patient
La tua dose settimanale di consigli sulla salute chiari e affidabili - scritti per aiutarti a sentirti informato, sicuro e in controllo.
Abbonandoti accetti i nostri Informativa sulla Privacy. Puoi annullare l'iscrizione in qualsiasi momento. Non vendiamo mai i tuoi dati.